Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 4/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MASP2 | O00187 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20077884 | 0.82 | EPHX1 (0.47) | CYP2C9 | |
| SCHEMBL3672272 | 0.81 | CYP2C9 (0.48) | ALDH1A1MEN1MAPTKMT2ACA2 | |
| SCHEMBL18235899 | 0.80 | CYP2C9 (0.39) | MEN1MAPTKMT2ACA2HPGD | |
| SCHEMBL19571325 | 0.80 | MEN1 (0.43) | ALDH1A1MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL11981491 | 0.80 | IDO1 (0.52) | ALDH1A1MEN1MAPTKMT2ACA2 | |
| SCHEMBL11981710 | 0.79 | LMNA (0.42) | ALDH1A1MEN1MAPTKMT2ACYP1A2 | |
| SCHEMBL12075395 | 0.79 | LMNA (0.42) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL16181284 | 0.79 | PARP1 (0.39) | CA2HPGDST14CYP2C9CYP2C19 | |
| SCHEMBL8399380 | 0.79 | MEN1 (0.51) | ALDH1A1MEN1KMT2ACA2HDAC1 | |
| SCHEMBL12288 | 0.78 | DNM1 (0.40) | ALDH1A1MEN1MAPTKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | ALDH1A1 543/4885MEN1 811/4885MAPT 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.